查看文章

Eur J Clin Invest 2011; 41 (10): 1133–1148

Background  Aggressive pituitary tumours are associated with substantial morbidity and mortality. Treatment options are often limited, and chemotherapy has been reserved as salvage therapy although historically results have often been disappointing. However, temozolomide, an oral alkylating agent, has recently demonstrated significant activity against these tumours. A DNA repair protein, 06methylguanineDNA methyltransferase (MGMT) has been suggested as a biomarker to predict response to temozolomide in pituitary tumours.

Materials and methods  This paper will review the current literature on temozolomide and pituitary tumours and discuss the recent controversy surrounding the value of determining the MGMT status in this tumour group. A PubMed search was performed to retrieve articles, using the terms ‘pituitary tumour’ and ‘temozolomide …